miravirsen and Hepatitis-C
miravirsen has been researched along with Hepatitis-C* in 7 studies
Reviews
3 review(s) available for miravirsen and Hepatitis-C
Article | Year |
---|---|
miRNA Targeting Drugs: The Next Blockbusters?
Only 20 years after the discovery of small non-coding, single-stranded ribonucleic acids, so-called microRNAs (miRNAs), as post-transcriptional gene regulators, the first miRNA-targeting drug Miravirsen for the treatment of hepatitis C has been successfully tested in clinical Phase II trials. Addressing miRNAs as drug targets may enable the cure, or at least the treatment of diseases, which presently seems impossible. However, due to miRNAs' chemical structure, generation of potential drug molecules with necessary pharmacokinetic properties is still challenging and requires a re-thinking of the drug discovery process. Therefore, this chapter highlights the potential of miRNAs as drug targets, discusses the challenges, and tries to give a complete overview of recent strategies in miRNA drug discovery. Topics: Drug Delivery Systems; Drug Discovery; Gene Expression Regulation; Hepacivirus; Hepatitis C; Humans; MicroRNAs; Oligonucleotides | 2017 |
MicroRNA-targeting therapeutics for hepatitis C.
MiR-122 is a liver-specific microRNA (miRNA) that plays a pivotal role in regulating hepatic functions such as lipid metabolism and stress response. The observation that hepatitis C virus (HCV) could only replicate in miR-122-positive hepatocytes led to the discovery that miR-122 is essential for HCV replication, and miR-122 is now one of the crucial host factors for anti-HCV therapy. Currently, the most advanced miR-122 targeting therapy is SPC3649 (miravirsen), a locked nucleic acid-modified oligonucleotide antagonizing miR-122. This review serves to provide information on the discovery and development of SPC3649, the first miRNA-targeted drug to enter human clinical trials, and introduce other miR-122-targeting therapeutics being developed for hepatitis C. Topics: Animals; Clinical Trials as Topic; Drug Delivery Systems; Drugs, Investigational; Hepatitis C; Humans; MicroRNAs; Oligonucleotides; Phosphorothioate Oligonucleotides | 2014 |
[Overview of locked nucleic acid(LNA)- SPC3649 and its application in HCV treatment].
Topics: Base Sequence; Hepacivirus; Hepatitis C; Humans; Molecular Sequence Data; Oligonucleotides; Phosphorothioate Oligonucleotides | 2011 |
Other Studies
4 other study(ies) available for miravirsen and Hepatitis-C
Article | Year |
---|---|
Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation-A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion.
Normothermic ex vivo liver perfusion (NEVLP) offers the potential to optimize graft function prior to liver transplantation (LT). Hepatitis C virus (HCV) is dependent on the presence of miRNA(microRNA)-122. Miravirsen, a locked-nucleic acid oligonucleotide, sequesters miR-122 and inhibits HCV replication. The aim of this study was to assess the efficacy of delivering miravirsen during NEVLP to inhibit miR-122 function in a pig LT model. Pig livers were treated with miravirsen during NEVLP or cold storage (CS). Miravirsen absorption, miR-122 sequestration, and miR-122 target gene derepression were determined before and after LT. The effect of miravirsen treatment on HCV infection of hepatoma cells was also assessed. NEVLP improved miravirsen uptake versus CS. Significant miR-122 sequestration and miR-122 target gene derepression were seen with NEVLP but not with CS. In vitro data confirmed miravirsen suppression of HCV replication after established infection and prevented HCV infection with pretreatment of cells, analogous to the pretreatment of grafts in the transplant setting. In conclusion, miravirsen delivery during NEVLP is a potential strategy to prevent HCV reinfection after LT. This is the first large-animal study to provide "proof of concept" for using NEVLP to modify and optimize liver grafts for transplantation. Topics: Animals; Antiviral Agents; Extracorporeal Circulation; Hepacivirus; Hepatitis C; Liver Transplantation; Male; Oligonucleotides; Perfusion; Swine; Virus Replication | 2017 |
The RNA revolution.
Topics: Animals; Ebolavirus; Hemorrhagic Fever, Ebola; Hepatitis C; Humans; MicroRNAs; Oligonucleotides; RNA; RNA, Small Interfering; Technology, Pharmaceutical | 2014 |
Miravirsen works against hepatitis C virus.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; MicroRNAs; Oligonucleotides | 2013 |
MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection.
Hepatitis C virus infection is the main cause of liver disease worldwide, often leading to chronic hepatitis. Recent studies have demonstrated that miRNA-122, a liver-specific miRNA, is required for HCV replication in hepatocytes by its binding to the 5' UTR of HCV. Down-regulation of miRNA-122 in vitro and in vivo has led to significant inhibition of viral replication. In the present article, we report the major recent findings on the potential therapeutic role of anti-miRNA-122 molecules. Topics: Base Sequence; Binding Sites; Cell Line; Gene Expression Regulation, Viral; Hepacivirus; Hepatitis C; Humans; Liver; MicroRNAs; Molecular Sequence Data; Oligonucleotides; Phosphorothioate Oligonucleotides; Virus Replication | 2011 |